Search PubMed⌕ Search

Biomedical subjects

S Yen

Publications and source records attributed to S Yen.

85 records · Page 5Linked to original sources
PubMed1976

Effect of megestrol acetate (Megace) on steroid metabolism and steroid-protein binding in the human prostate.

Megestrol acetate (Megace), an antiandrogen, was administered in a dosage of 80 mg daily to 6 patients with benign prostatic hypertrophy (BPH) for 4 to 25 days prior to transurethral resection of the prostate (TURP). Surgical tissue from drug-treated patients was compared to untreated controls in regard to: 1) the enzymatic reduction of testosterone (T) and dihydrotestosterone (DHT); 2) DHT binding to a cytosol receptor protein; 3) tissue levels of endogenous dihydrotestosterone and androstanediols (diols). When minced prostate was incubated with 3H-T and 14C-androstenedione for 1 h at 37 C, prostate 5alpha-reductase activity, measured as reduced products formed from substrate, decreased to 31% and 39%, respectively, of the control values. Prostate 3-oxido-reductase enzyme activity, measured as diols formed from 3H-DHT, was decreased to neglible values in Megace-treated patients compared to an 8.7% conversion to diols in controls. No 3H-DHT binding to a cytosol receptor protein could be demonstrated in 4 out of 5 prostates from Megace-treated patients, whereas the presence of such a receptor was noted in 14 out of 17 untreated controls. Endogenous DHT levels in Megace-treated patients averaged 1.1 ng/g (SE = 0.26), significantly less than the average of 3.9 ng/g (SE = 0.49) found in controls (P less than 0.001). No significant difference was noted in endogenous diols. In addition to these effects on tissue, Megace significantly decreased plasma levels of T, LH, and FSH at the end of the 4- to 25-day period; plasma prolactin levels did not change. Continued studies of Megace for the possible treatment of benign prostatic hypertrophy may be warranted since the drug appears to block several important biochemical steps which mediate the effects of androgen on the human prostate.

3-Oxo-5-alpha-Steroid 4-Dehydrogenase↗
PubMed1975

Coffee drinking and cancer of the lower urinary tract.

The relationship between coffee drinking and cancer of the lower urinary tract (LUT) was investigated by a case-control study of white women identified from hospitals in urban areas of Massachusetts and Rhode Island. Data on coffee drinking, tea drinking, use of coffee additives, and cigarette smoking were obtained by mail questionnaire. Information was available for 135 women with LUT cancer and 390 controls. For women who usually drank 1+ cups of coffee per day, the risk ratio of having LUT cancer was 2.1 (95 percent confidence limits, 1.1-4.3), compared to a risk of 1 for women who drank less or not at all. However, no dose-response relationship was demonstrated between LUT cancer and usual daily coffee consumption or "cup-years" of coffee drinking. The association of coffee with disease was no different, whether decaffeinated, nondecaffeinated, regular, or instant coffee had been drunk, or whether the coffee was brewed strong or weak. Use of nondairy creamers, saccharin, or cyclamates was not associated with increased risk of disease. The risk of LUT cancer for cigarette smokers relative to nonsmokers was 1.6 (1.0-2.4). The attendant dose-response relationship was statistically significant. The absence of a dose-response relationship between coffee drinking and LUT cancer suggested that the association observed was noncasual.

Aged↗
PubMedDate not supplied

Presence of dentin phosphoprotein in molars of a patient with dentinogenesis imperfecta type II.

Dentin phosphoprotein (DPP) is the major noncollagenous protein component of the dentin extracellular matrix. This highly acidic phosphorylated protein is solely expressed by the ectomesenchymal-derived odontoblast cells of the tooth organ. Several biochemical studies have suggested diminished levels of, or even the absence of, this protein, which is associated with the human genetic disease dentinogenesis imperfecta (DGI) type II. However, more recent molecular studies have established that the DPP gene locus is not localized to the region of human chromosome 4 (4q13-q21), where several previous linkage analysis studies have mapped DGI types II and III. The purpose of this study was to determine the presence or absence of DPP in the dentition of a patient affected with DGI type II using a sensitive and specific immunodetection method with a polyclonal antibody against mouse DPP. Our results indicate that a 95-kDa protein, immunologically crossreactive with the DPP antibody, was detected within the dentin extracellular matrix of molars isolated from both a proband affected with DGI-II and from an age-matched normal individual. In addition, both DGI-II and normal individuals showed comparable DPP in situ degradation associated with dentin extracellular matrix maturation. These results strongly support the hypothesis that the DPP structural gene does not produce the gene product primarily responsible for the human genetic disease DGI type II.

Adult↗